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Abstract 
Carboplatin and cisplatin are chemotherapeutic agents that are used extensively for treating 
epithelial ovarian cancer. These drugs can be highly effective, yet tumors are frequently refractory to 
treatment or become resistant upon tumor relapse. Epigenetic silencing, particularly at promoter 
regions of genes regulates important cell function and has been associated with all stages of tumor 
formation and progression and may contribute to therapy response. We analyzed the epigenome of 
50 primary ovarian tumors and 12 normal ovarian samples using an array based method previously 
developed in our lab and associated Affymetrix U133 expression data. We then identified gene 
candidates that segregate patients based on platinum sensitivity and patient survival. These 
candidates were then pooled into a genome-wide RNAi-based screen where we validated a gene 
encoding a chromatin remodeling protein, CHD3, a member of the Mi-2 NuRD complex, and show 
that it is linked to chemoresistance. CHD3 is silenced through an epigenetic mechanism in both 
ovarian cancer cell lines and primary ovarian tumors. When ovarian cancer cell lines that are 
transcriptionally silenced for CHD3 are challenged with carboplatin they display a striking slow 
growth phenotype as well as increased resistance to the chemotherapy drugs carboplatin and 
cisplatin. Taken together, we provide the first evidence for a role for CHD3 as an important mediator 
of chemoresistance in ovarian cancer. Furthermore, CHD3 might represent a response predictor and 
potential therapeutic target for predicting chemoresistance in this disease. 
 
